FTC settlement
This article was originally published in The Tan Sheet
Executive Summary
Vineet Chhabra and his companies Dynamic Health of Florida and Chhabra Group are required to "rely on competent and reliable scientific evidence" to substantiate claims for their children's product Pedia Loss under a settlement reached with FTC, the commission announced April 6. FTC specifically pointed to claims that the product "suppresses appetite, increases fat burning and slows carbohydrate absorption." The marketers also are prohibited from making unsubstantiated claims for Fabulously Feminine, which they claimed would "increase a woman's libido, sexual desire and sexual satisfaction"...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.